Boriani, Giuseppe (57675336900)Giuseppe (57675336900)BorianiProietti, Marco (57202956034)Marco (57202956034)ProiettiLaroche, Cécile (7102361087)Cécile (7102361087)LarocheFauchier, Laurent (7005282545)Laurent (7005282545)FauchierMarin, Francisco (57211248449)Francisco (57211248449)MarinNabauer, Michael (7004310943)Michael (7004310943)NabauerPotpara, Tatjana (57216792589)Tatjana (57216792589)PotparaDan, Gheorghe-Andrei (6701679438)Gheorghe-Andrei (6701679438)DanKalarus, Zbigniew (56266442700)Zbigniew (56266442700)KalarusTavazzi, Luigi (7102746954)Luigi (7102746954)TavazziMaggioni, Aldo P (57203255222)Aldo P (57203255222)MaggioniLip, Gregory Y. H (57216675273)Gregory Y. H (57216675273)Lip2025-06-122025-06-122019https://doi.org/10.1093/europace/euz032https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069883184&doi=10.1093%2feuropace%2feuz032&partnerID=40&md5=904b4006d99206597904357789bbfa1chttps://remedy.med.bg.ac.rs/handle/123456789/5473Aims: In recent years, stroke prevention in patients with atrial fibrillation (AF) has radically changed, with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis are needed. Methods and results: We report 1-year follow-up data from the EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes were assessed according to antithrombotic therapy. At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with NOACs only; and 1163 (12.0%) with antiplatelet and oral anticoagulant. At 1-year follow-up, there was a low rate of stroke (0.7%) and any thromboembolic event (TE) (1.2%), while haemorrhagic events occurred in 222 patients (2.3%). Cardiovascular (CV) death and all-cause death occurred in 3.9% and 5.2% of patients, respectively. Cumulative survival for all the three main outcomes considered was highest amongst patients treated only with NOACs (P < 0.0001). Multivariable-adjusted Cox regression analysis found that VKA or NOACs use was independently associated with a lower risk for any TE/acute coronary syndrome/CV death, while all treatments were independently associated with a lower risk for CV death and all-cause death. Conclusion: The 1-year follow-up of EORP-AF General Long-Term Registry reported a low occurrence of thromboembolic and haemorrhagic events, although mortality was high. Both VKA and NOACs were associated with a lower risk of all main adverse outcomes. All treatments were associated with a lower risk for CV death and all-cause death. © 2019 Published on behalf of the European Society of Cardiology. All rights reserved.Antithrombotic therapyAtrial fibrillationEORP-AF registryObservational registriesOutcomesStroke